Brain disorders (Amsterdam, Netherlands)最新文献_第6页

Re-visiting mpox: Stealth assault on the brain and emerging biomedical research insights 重新审视 mpox：对大脑的隐形攻击和新的生物医学研究见解

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-10-16 DOI: 10.1016/j.dscb.2024.100169

Abhimanyu Thakur

{"title":"Re-visiting mpox: Stealth assault on the brain and emerging biomedical research insights","authors":"Abhimanyu Thakur","doi":"10.1016/j.dscb.2024.100169","DOIUrl":"10.1016/j.dscb.2024.100169","url":null,"abstract":"<div><div>The recent global outbreak of mpox virus (MPXV) infections has reignited interest in this zoonotic disease, mpox. As of August 2024, mpox continues to pose significant global health challenges, with ongoing transmission in Africa, the Americas, and Europe. This article examines the neurological implications of MPXV infection, synthesizing current research to provide biomedical insights into the virus's potential impact on the central nervous system (CNS). The neuroinvasive potential of MPXV and the rare but serious complication of encephalomyelitis have been discussed. The article explores advances in mpox research, including insights from animal models such as dogs, squirrels, and mice. Further. the application of bioinformatics and machine learning techniques for enhanced mpox detection and potential therapeutics for mpox and related neurological complications have discussed. The article also addresses the current state of mpox vaccines, existing resources, and future directions for vaccine development. By examining the molecular characteristics of MPXV, its mechanisms of cellular invasion, and its effects beyond cutaneous manifestations, this article provides a comprehensive overview of the current understanding of mpox neurological implications. Eventually, the major research priorities and potential strategies for mitigating the neurological impact of MPXV infections have been highlighted in the context of ongoing global health challenges.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100169"},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the potential: Woodfordia fruticosa Kurz in Alzheimer's disease management - A concise review 挖掘潜力：库尔兹木芙蓉（Woodfordia fruticosa Kurz）在阿尔茨海默病治疗中的应用--简明综述

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-10-16 DOI: 10.1016/j.dscb.2024.100171

Sanjukta Sen , Shreyasi Meur , Gouranga Nandi , Dipanjan Karati

{"title":"Unlocking the potential: Woodfordia fruticosa Kurz in Alzheimer's disease management - A concise review","authors":"Sanjukta Sen , Shreyasi Meur , Gouranga Nandi , Dipanjan Karati","doi":"10.1016/j.dscb.2024.100171","DOIUrl":"10.1016/j.dscb.2024.100171","url":null,"abstract":"<div><div>Alzheimer's disease (AD), a progressive neurodegenerative disorder, epitomizes the intricate interplay between genetic predisposition and molecular pathology, resulting in the relentless deterioration of neuronal structures within the brain. Characterized by the formation of amyloid-beta plaques and tau protein tangles, this condition disrupts synaptic connections, leading to profound cognitive impairment. The utilization of medicinal herbs in the treatment of AD has garnered considerable attention within scientific research due to their potential neuroprotective and therapeutic properties. The World Health Organization has long noted and brought to the attention of many countries the growing public interest in medicinal plants and their products to cure various disorders, including AD due to their potential neuroprotective properties. The ethnomedicinal relevance of the plant <em>Woodfordia fruticosa</em> Kurtz has been reflected in the art of Ayurveda and India's traditional healing system, which reveals its widespread use in Ayurvedic treatments. Numerous chemical compounds found in <em>Woodfordia fruticosa</em> (WF) have been shown to be biologically active against the predisposing factors of AD. The flower extract of WF is particularly effective in inhibiting key enzymes like AChE and BuChE that are involved in AD, while its leaf and stem extracts also contribute to this effect. <em>In vivo</em> studies demonstrate that the flower extract can reverse memory impairment and reduce elevated enzyme levels in animal models. This review highlights the comprehensive potential of <em>Woodfordia fruticosa</em> Kurz in AD management, the multifaceted activities of WF, spanning enzyme inhibition, cholinesterase inhibition, and neuroprotection, underscore its promise as a natural therapeutic agent for AD.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100171"},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Percheron Artery Stroke and Reperfusive therapies: A systematic review and meta-analysis 佩尔切隆动脉中风与再灌注疗法：系统回顾和荟萃分析

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-10-15 DOI: 10.1016/j.dscb.2024.100167

Giulio Papiri , Emanuele Puca , Matteo Marcucci , Cristina Paci , Donatella Petritola , Stefania Bifolchetti , Sandro Sanguigni , Fabio Di Marzio , Gabriella Cacchiò , Giordano D'Andreamatteo , Claudia Cagnetti

{"title":"Percheron Artery Stroke and Reperfusive therapies: A systematic review and meta-analysis","authors":"Giulio Papiri , Emanuele Puca , Matteo Marcucci , Cristina Paci , Donatella Petritola , Stefania Bifolchetti , Sandro Sanguigni , Fabio Di Marzio , Gabriella Cacchiò , Giordano D'Andreamatteo , Claudia Cagnetti","doi":"10.1016/j.dscb.2024.100167","DOIUrl":"10.1016/j.dscb.2024.100167","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Percheron Artery Stroke, affecting bilateral paramedian thalamic structures, accounts for 0.1–0.4 % of all acute ischemic strokes. Little is known about disability or mortality outcomes in patients receiving intravenous thrombolysis (IVT) or endovascular treatment (EVT), therefore a systematic review was carried out.</div></div><div><h3>Methods</h3><div>A systematic search of Pubmed, Embase and Scopus databases for all kind of studies regarding Percheron Artery Stroke was performed. The review is registered in INPLASY (202410059). In total, 1895 papers were screened; 197 studies were included, consisting exclusively in case reports, retrospective series and conference abstracts. Data from 448 patients were analyzed in logistic regression.</div></div><div><h3>Results</h3><div>Both IVT (OR<sub>IVT</sub> = 3.08; 95 % CI 1.4 – 6.7; <em>p</em> = 0.005) and EVT (OR<sub>EVT</sub> = 5.77; 95 % CI 1.69 – 19.7; <em>p</em> = 0.005) were associated with reduced disability, as well as exclusive thalamic involvement (OR = 3.24; CI 2.1 – 5.1; <em>p</em> < 0.001) and higher Glasgow Coma Scale score (GCS) on admission (OR = 1.2; 95 % CI 1.12 – 1.28; <em>p</em> < 0.001). GCS (OR = 0.73, 95 % CI 0.63 – 0.82; <em>p</em> < 0.001) and exclusive thalamic involvement (OR = 0.36; 95 % CI 0.16 – 0.74; <em>p</em> = 0.005) were associated with lesser mortality, while IVT displayed a non-significant trend towards reduced mortality (OR<sub>IVT</sub> = 0.13; 95 % CI 0.01 – 1.04; <em>p</em> = 0.056).</div></div><div><h3>Conclusion</h3><div>The present work, albeit summarizing data coming from low quality sources, suggests an association between both EVT/IVT and better outcomes in paramedian bilateral thalamic strokes.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100167"},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating the role of structural connectivity in the individuals with moderate hearing loss 研究结构连接在中度听力损失患者中的作用

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-10-08 DOI: 10.1016/j.dscb.2024.100165

AHM Ruhul Quddus , Mst Shahnaj Pervin , Artyom Zinchenko , Md Mamun Al Amin

{"title":"Investigating the role of structural connectivity in the individuals with moderate hearing loss","authors":"AHM Ruhul Quddus , Mst Shahnaj Pervin , Artyom Zinchenko , Md Mamun Al Amin","doi":"10.1016/j.dscb.2024.100165","DOIUrl":"10.1016/j.dscb.2024.100165","url":null,"abstract":"<div><div>Hearing loss has been identified as a risk factor for cognitive decline. The processing of auditory information relies on a well-connected neuronal network. Previous studies have found white matter abnormalities in individuals with hearing loss, but the structural connectivity and microstructural properties of white matter in individuals with moderate hearing loss remain unclear.</div><div>To examine the integrity of white matter, identify vulnerable structural connectivity, and assess network topology, we examined major white matter tracts in elderly individuals with moderate hearing loss (MHL) (>30 dB) and compared them to age-matched controls with good hearing (GH).</div><div>We observed that the fractional anisotropy of the right corticospinal tract and left superior longitudinal fasciculus – parietal was higher in subjects with MHL. Additionally, we identified a disrupted network centered on the left putamen in MHL, involving eight brain regions. Network topology analysis showed reduced betweenness centrality and small-world network in MHL. Interestingly, the fractional anisotropy of the forceps major tract and left uncinate tracts were correlated with hearing status.</div><div>Our findings suggest that MHL is associated with putamen-centered disruptions in structural connectivity. The increased fractional anisotropy of the right corticospinal tract may be a compensatory mechanism, as it projects fibers to the right putamen. Overall, these results provide valuable insights into the impact of hearing loss on white matter integrity and may inform the development of new treatments to prevent its progression.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100165"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142434085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroprotective mechanisms and ameliorative activities of quercetin in cisplatin-induced cerebellum neurotoxicity in rat models 槲皮素在顺铂诱导的小脑神经毒性大鼠模型中的神经保护机制和改善活性

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-10-05 DOI: 10.1016/j.dscb.2024.100166

Sunday Aderemi Adelakun , Babatunde Ogunlade , Julius Akomaye Aniah , Oladipupo Nifemi Akinyemi

{"title":"Neuroprotective mechanisms and ameliorative activities of quercetin in cisplatin-induced cerebellum neurotoxicity in rat models","authors":"Sunday Aderemi Adelakun , Babatunde Ogunlade , Julius Akomaye Aniah , Oladipupo Nifemi Akinyemi","doi":"10.1016/j.dscb.2024.100166","DOIUrl":"10.1016/j.dscb.2024.100166","url":null,"abstract":"<div><div>Cisplatin (CP) is a highly effective antitumor agent, but its clinical use is limited due to critical adverse reactions including neurotoxicity. Quercetin (QC) is a naturally occurring phytochemical with promising bioactive effects. This study investigated the Neuroprotective mechanisms and ameliorative activities of quercetin in cisplatin-induced cerebellum neurotoxicity in rat models.</div><div>The rats were randomly divided into five groups of six (<em>n</em> = 6) rats. Group A, served as control. Group B, received a single dose of 10 mg/kg body weight (bwt) of CP (i.p.) on the first day. Group C received 30 mg/kg bwt of QC. Group D received a single dose of 10 mg/kg bwt CP on the first day followed by 30 mg/kg bwt of QC. Group E received 30 mg/kg bwt of QC per day followed by a single dose of 10 mg/kg bwt of CP on the last day. The treatment lasted for 35 days after which the novel-object recognition memory test (NORT) was used to assess non-spatial memory function. Brain neurochemical status was assessed and brain tissues were processed for histology.</div><div>Quercetin increased weight loss and cognitive performance in CP-treated rats by enhancing the exploration of unfamiliar objects. Quercetin protects the brain from CP-mediated alterations in oxidative status, as well as brain metabolic enzyme indicators. It also decreased IL-6, IL-1, and TNF-α, and NF-ĸB expression, restored brain metabolic enzyme activities, increased neurotransmitters, and prevented neuromorphological alterations.</div><div>In conclusion, quercetin protects rats’ brains against CP-induced cerebellum neurotoxicity via oxidative stress inhibition and down-regulation of inflammation.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100166"},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel approaches targeting α-Synuclein for Parkinson's Disease: Current progress and future directions for the disease-modifying therapies 针对帕金森病α-突触核蛋白的新方法：疾病改变疗法的当前进展和未来方向

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-09-20 DOI: 10.1016/j.dscb.2024.100163

David Baggett , Alex Olson , Mayur S. Parmar

{"title":"Novel approaches targeting α-Synuclein for Parkinson's Disease: Current progress and future directions for the disease-modifying therapies","authors":"David Baggett , Alex Olson , Mayur S. Parmar","doi":"10.1016/j.dscb.2024.100163","DOIUrl":"10.1016/j.dscb.2024.100163","url":null,"abstract":"<div><div>Parkinson's Disease (PD) is a common and debilitating neurodegenerative disorder affecting millions worldwide. The hallmark pathological feature of PD is the accumulation and aggregation of α-Synuclein (α-Syn), a protein involved in synaptic function and neuronal survival. The formation of α-Syn aggregates, also known as Lewy bodies and Lewy neurites, leads to neuronal dysfunction and death, resulting in PD's characteristic motor and non-motor symptoms. Current treatments for PD are mainly symptomatic and do not address the underlying cause of the disease. Therefore, there is an urgent need for disease-modifying therapies that can prevent, slow, or reverse the progression of PD by targeting α-Syn aggregation. In this review, we summarize the current status of pharmacological interventions that aim to reduce α-Syn levels in PD and other Synucleionopathies by various mechanisms, such as inhibiting α-Syn aggregation, enhancing α-Syn clearance, modulating α-Syn-related enzymes, or blocking α-Syn transmission. We focus on agents that have reached phase 1 or 2 clinical trials and provide an overview of their preclinical and clinical data and their safety and efficacy profiles. While fewer candidates have shown positive results in clinical trials, they are awaiting further evaluation in larger and longer-term studies. None of the placebo-controlled, blind trials, except Prasinezumab, have demonstrated efficacy. These novel disease-modifying therapy approaches can potentially change the landscape of PD treatment and improve the quality of life for PD patients.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"16 ","pages":"Article 100163"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute intermittent porphyria: A case report with an unlisted HMBS gene variant (c.345–2A>C) 急性间歇性卟啉症：一例未列入清单的 HMBS 基因变异（c.345-2A>C）病例报告

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-09-01 DOI: 10.1016/j.dscb.2024.100160

Julien Lerusse , Dominique Dive , François Charles Wang

引用次数: 0

High-intensity body weight interval training modifies neurochemistry in AD disease: Preliminary data from a randomized control trial 高强度体重间歇训练可改变注意力缺失症的神经化学成分：随机对照试验的初步数据

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-09-01 DOI: 10.1016/j.dscb.2024.100159

Vernon Furtado-da-Silva , Domingos Edno Castro Ribeiro , Célio José Borges , Ivete de Aquino Freire , Angeliete Garces Militão , Daniel Delani , Luis Gonzaga de Oliveira Gonçalves , João Rafael Valentim-Silva

{"title":"High-intensity body weight interval training modifies neurochemistry in AD disease: Preliminary data from a randomized control trial","authors":"Vernon Furtado-da-Silva , Domingos Edno Castro Ribeiro , Célio José Borges , Ivete de Aquino Freire , Angeliete Garces Militão , Daniel Delani , Luis Gonzaga de Oliveira Gonçalves , João Rafael Valentim-Silva","doi":"10.1016/j.dscb.2024.100159","DOIUrl":"10.1016/j.dscb.2024.100159","url":null,"abstract":"<div><h3>Background</h3><p>Alzheimer's disease (AD) is an incurable condition characterized by cognitive and neurochemical impairments, necessitating the exploration of alternative interventions. Physical exercise shows promise, but the effects of high-intensity protocols on the neurochemical aspects of AD-related neurodegeneration remain poorly explored.</p></div><div><h3>Objective</h3><p>This study examines the effects of high-intensity body weight interval training (PMED) on brain-derived neurotrophic factor (BDNF) and phosphorylated-TAU protein (p-TAU) in AD disease.</p></div><div><h3>Methods</h3><p>Thirty-four elderly individuals diagnosed with AD disease were divided into two groups of 17 subjects: GCP, which participated in PMED (30 min at 80–90 % of maximal cardiac frequency three times per week), and GCS, which had no interventions. Pre- and post-measurements of BDNF and p-TAU were conducted.</p></div><div><h3>Results</h3><p>The GCS group showed no changes in his neurochemical factors (<em>p</em> > 0.05). In contrast, the GCP group experienced increased BDNF levels and decreased p-TAU blood concentrations (<em>p</em> < 0.0001 for both).</p></div><div><h3>Conclusions</h3><p>PMED increased BDNF and reduced p-TAU concentrations, improving neurochemistry in AD disease. This can open an avenue of new interventions using high-intensity body weight interval training, including, in home base programs, which can be an advantage to engagement.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100159"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000441/pdfft?md5=ebc5439dd2afab8ee51fef73156e8ca0&pid=1-s2.0-S2666459324000441-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decision making for decompressive craniectomy (DC) in patients with malignant middle cerebral artery infarction (mMCAI) based on inclusion criteria of clinical studies: A systematic review 根据临床研究的纳入标准为恶性大脑中动脉梗死（mMCAI）患者做出减压开颅术（DC）决策：系统综述

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-09-01 DOI: 10.1016/j.dscb.2024.100161

Ali Mulhem

{"title":"Decision making for decompressive craniectomy (DC) in patients with malignant middle cerebral artery infarction (mMCAI) based on inclusion criteria of clinical studies: A systematic review","authors":"Ali Mulhem","doi":"10.1016/j.dscb.2024.100161","DOIUrl":"10.1016/j.dscb.2024.100161","url":null,"abstract":"<div><p>The introduction of DC as therapy for mMCAI reduced the mortality rate. We aimed to summarise the inclusion criteria in studies of DC to provide a guidance of patients selection.</p><p>We searched 7 databases from inception till 31st December 2021 with an updated search on 25th June 2024. We included studies if they compared patients with mMCAI who underwent DC in addition to medical treatment and patients managed with medical care alone.</p><p>32 studies were published between 1995 and 2022. All studies stated that infarction of at least >50 % of MCA territory was the main inclusion criterion. The mean age of patients was 53 but varied from 18 to 89. Most studies (<em>n</em> = 27) included patients >60 years. Clinical inclusion criteria were NIHSS>15, used by 15 studies, and GCS ≥ 6, used by 9 studies. Radiological criteria were MLS ≥ 5 mm (<em>n</em> = 6), and signs of brain herniation (<em>n</em> = 8). The stroke duration was an inclusion criterion in 17 studies; it varied from 6 h to 96 h, with 10 studies limiting the time window to <48 h since the infarct onset. Lastly, 23 studies excluded patients with previous disabilities measured as mRS > 1 or patients with signs of brain death.</p><p>Inclusion criteria for mMCAI to undergo DC varied among studies; however, there were many similarities, namely a large volume of infarction, wide age range without exclusion of older patients, less severe neurological status as assessed with NIHSS or GCS, no previous physical disability, clear midline shift on imaging and the first two days since the onset of stroke.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100161"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000465/pdfft?md5=9f7a0e7475a65578c9f461dd43ccfb96&pid=1-s2.0-S2666459324000465-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in selective therapeutic targeting of functionalized nanomaterials to neurovascular units in overcoming the gaps in neurovascular therapy 功能化纳米材料对神经血管单元的选择性治疗靶向在克服神经血管治疗空白方面的最新进展

Brain disorders (Amsterdam, Netherlands) Pub Date : 2024-09-01 DOI: 10.1016/j.dscb.2024.100162

Sakshi Goswami , Nickolay K. Isaev , Alla B. Salmina , Suresh Vir Singh Rana , Sergey N. Illarioshkin , Yeshvandra Verma

{"title":"Recent developments in selective therapeutic targeting of functionalized nanomaterials to neurovascular units in overcoming the gaps in neurovascular therapy","authors":"Sakshi Goswami , Nickolay K. Isaev , Alla B. Salmina , Suresh Vir Singh Rana , Sergey N. Illarioshkin , Yeshvandra Verma","doi":"10.1016/j.dscb.2024.100162","DOIUrl":"10.1016/j.dscb.2024.100162","url":null,"abstract":"<div><p>Neurodegenerative disorders are difficult to treat because of natural barrier in the brain. Moreover, neurovascular units seem to be essential targets/mediators of the nervous system cytoprotective effects. Functionalized nanomaterials have gained significant prominence in the medical domain due to their extensive utilization in targeted drug delivery and therapeutics within the neurovascular system. Their remarkable potential in neurovascular therapy has been demonstrated, highlighting their effectiveness in this field. A systematic summary of the specific applications and limitations of functionalized nanomaterials in the targeted delivery system is essential for developing smart therapies to overcome the gaps in neurovascular therapy for the treatment of neurological disorders. The objective of present article was to highlight the advancements in recent therapies support the potential role of functionalized nanomaterials to tackle the difficulties in targeted delivery systems for neurodegenerative disorders. We review the role of functionalized nanomaterials as therapeutics within the neurovascular units and their potential to lead to more sophisticated and smart treatment techniques despite some obstacles, given to the patients of neurological disorders, particularly when paired with multimodal drugs who are likely to benefit from cytoprotection. This review also addresses the current understanding, gaps, and issues to be resolved.</p></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"15 ","pages":"Article 100162"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666459324000477/pdfft?md5=bb69e994fe8a72f4a7ef8ad9324fcc86&pid=1-s2.0-S2666459324000477-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0